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Abstract
Somatostatin has been discovered as a somatotroph release inhibitory factor (SRIF), and it has been
demonstrated that SRIF and its analogs can inhibit hormone secretion and control the neoplastic bulk
of several endocrine tumours. In vitro studies have contributed to the current knowledge of the
mechanisms by which SRIF and its analogs may influence endocrine tumour proliferation, opening
the way to new possible therapeutic strategies. Here, we focus on the studies concerning the
antiproliferative effects of SRIF and its analogs that provide the basis for future investigations, both at
basic and clinical levels, into the application of SRIF analogs in the endocrine field.
Introduction and context
On the basis of the antisecretory and antiproliferative
effects of somatostatin [somatotroph release inhibitory
factor (SRIF)] and its analogs on normal and neoplastic
endocrine cells, these compounds have been widely used
in the medical field. Many studies have demonstrated
that they activate several intracellular pathways, depend-
ing on receptor subtype and target cells [1], with highly
variable effects depending on the tissue [2]. Currently
available SRIF analogs (such as octreotide and lanreo-
tide) are indeed capable of normalizing growth hormone
and insulin-like growth factor 1 (IGF-1) levels and of
controlling tumour growth in a substantial portion of
can effectively suppress the production of bioactive
peptides and hormones by the tumour cells, and in some
cases may display antiproliferative effects. It has been
indicated that the inhibitory effects of SRIF and its
analogs depend on tissue SRIF receptor (SSTR) expres-
sion pattern, agonist-binding profile, and SSTR effector
coupling [3]. The clinically available SRIF analogs do
indeed display slight differences in SSTR affinity profile;
octreotide shows higher affinity for SSTR5 as compared
with lanreotide and exhibits some SSTR3 affinity.
Moreover, the two compounds have different pharma-
cokinetic profiles depending on the formulation, which
might influence the antitumoural effects [4]. There is also
evidence indicating that inhibition of cell proliferation
may occur independently of the effects on hormone
secretion [5-7], possibly providing an explanation for
resistance to somatostatin analogs [8]. In the field of
pituitary adenomas, predictive indices for response to
SRIF analogs are a decrease in hormone levels after short-
term SRIF analog treatment, a positive octreoscan [9],
and previous radiotherapy [10]. However, these para-
meters do not reliably predict antiproliferative effects of
somatostatin analogs and do not seem applicable for
neuroendocrine tumours [11].
Recent advances
Several studies to elucidate SSTR expression pattern in
endocrine tumours have been performed recently.
Besides pituitary adenomas [3,12], other endocrine
tumours display a variable SSTR expression pattern:
thyroid tumours deriving from follicular [13] and
parafollicular [14,15] cells, adrenocortical tumours
[16], and bronchial [17] and gastroenteropancreatic
[18,19] neuroendocrine tumours. Most of these studies
correlate SSTR expression pattern with functional data
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specific endocrine tumour subsets, linking the efficacy of
these drugs to their affinity for SSTR2. Indeed, it has been
indicated that SSTR2 expression level might be a critical
factor affecting both tumour progression and SRIF
analog treatment outcome [20] since SSTR2 re-expres-
sion by gene transfer is able to improve sensitivity
toward SSTR2-interacting drugs [21]. The mechanism by
which SRIF inhibits endocrine cell proliferation has been
widely investigated in immortalized cell lines as well as
in endocrine tumour primary cultures, demonstrating
the involvement of tyrosine phosphatases [22] that
might trigger apoptotic changes [23,24]. Moreover,
SRIF and its analogs can cause decreases in cell
proliferation [25,26], cell cycle inhibition [27], and
growth arrest [23], also acting through the PI3K/Akt
signaling pathway [28]. These results confirm that SSTR2
is an important receptor subtype in transducing the
antiproliferative signals of SRIF, but they also indicate
that more than one SSTR is able to induce antiprolifera-
tive effects. Multiple subtypes may indeed cooperate to
induce growth arrest since these receptors can homo- and
hetero-dimerize with other G protein-coupled receptors
[29]. Besides the direct actions on endocrine neoplastic
cells, SRIF and its analogs can indirectly influence cell
proliferation by inhibiting production and secretion of
many angiogenic factors [30]. Moreover, it was recently
demonstrated that SRIF analog treatment might result
in biochemical/neuroradiological disease remission in a
subset of acromegalic patients [31], suggesting that
medical therapy might actually cure acromegaly in
selected patients.
Implications for clinical practice
The studies performed so far indicate that the antipro-
liferative effect of SRIF analogs on endocrine tumours
depends on tissue SSTR expression pattern (mainly
SSTR2), as well as on the different binding profiles of
the various agonists, and SSTR-effector coupling. There-
fore, the employment of SRIF analogs for ‘oncologic’
purposes should be based on both clinical and mole-
cular tumour characterization of each patient in order to
perform a really tailored targeted therapy. This implies a
strict collaboration among endocrinologists, oncologists,
nuclear medicine experts, surgeons, pathologists, and
molecular biologists in order to provide correct indica-
tions for the therapeutical use of SRIF analogs. In vivo and
in vitrodatadoindeedindicatethatcurrentlyavailableSRIF
analogs and new upcoming compounds can achieve
significant results in terms of tumour volume control in
endocrine tumours, especially pituitary adenomas
[32,33], but further clinical and basic studies are needed
to confirm this effect.
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